Last reviewed · How we verify

Xarlin (Levocetirizine)

HK inno.N Corporation · FDA-approved active Small molecule

Xarlin (Levocetirizine) is a H1-receptor antagonist (second-generation antihistamine) Small molecule drug developed by HK inno.N Corporation. It is currently FDA-approved for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis. Also known as: Cosalin (Petasites hybridus CO2 extract), Xyarin (levocetirizine).

Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms.

Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms. Used for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.

At a glance

Generic nameXarlin (Levocetirizine)
Also known asCosalin (Petasites hybridus CO2 extract), Xyarin (levocetirizine)
SponsorHK inno.N Corporation
Drug classH1-receptor antagonist (second-generation antihistamine)
TargetH1 receptor
ModalitySmall molecule
Therapeutic areaAllergy/Immunology
PhaseFDA-approved

Mechanism of action

Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It crosses the blood-brain barrier minimally, reducing sedation compared to first-generation antihistamines. By competitively blocking H1 receptors, it prevents histamine-mediated allergic responses including itching, urticaria, and rhinitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Xarlin (Levocetirizine)

What is Xarlin (Levocetirizine)?

Xarlin (Levocetirizine) is a H1-receptor antagonist (second-generation antihistamine) drug developed by HK inno.N Corporation, indicated for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.

How does Xarlin (Levocetirizine) work?

Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms.

What is Xarlin (Levocetirizine) used for?

Xarlin (Levocetirizine) is indicated for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.

Who makes Xarlin (Levocetirizine)?

Xarlin (Levocetirizine) is developed and marketed by HK inno.N Corporation (see full HK inno.N Corporation pipeline at /company/hk-inno-n-corporation).

Is Xarlin (Levocetirizine) also known as anything else?

Xarlin (Levocetirizine) is also known as Cosalin (Petasites hybridus CO2 extract), Xyarin (levocetirizine).

What drug class is Xarlin (Levocetirizine) in?

Xarlin (Levocetirizine) belongs to the H1-receptor antagonist (second-generation antihistamine) class. See all H1-receptor antagonist (second-generation antihistamine) drugs at /class/h1-receptor-antagonist-second-generation-antihistamine.

What development phase is Xarlin (Levocetirizine) in?

Xarlin (Levocetirizine) is FDA-approved (marketed).

What are the side effects of Xarlin (Levocetirizine)?

Common side effects of Xarlin (Levocetirizine) include Somnolence, Headache, Fatigue, Dry mouth.

What does Xarlin (Levocetirizine) target?

Xarlin (Levocetirizine) targets H1 receptor and is a H1-receptor antagonist (second-generation antihistamine).

Related